EE143 Cost-Effectiveness of Ocrelizumab in First-Line Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Chile

Abstract

Authors

E. Vásquez P. Lasalvia M. Rozas C. Gejman

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×